GSK blijft streven naar uitgebreide indicaties voor Arexvy in andere regio’s, waaronder de Verenigde Staten en Japan. Het vaccin is momenteel goedgekeurd in meer dan 60 landen voor personen van 60 ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

Investing.com -- GSK (NYSE: GSK) heeft vrijdag bekendgemaakt dat het Europees Geneesmiddelenbureau (EMA) haar aanvraag heeft geaccepteerd om het gebruik van het respiratoir syncytieel virus (RSV) ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...

Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's ...